aod9604 clinical trial obesity A completed AOD-9604 is not automatically a positive AOD-9604 result. FDA PCAC materials describe OPTIONS as a double-blind, randomized, placebo-controlled study in 502 adults with obesity. The briefing states that the B12 - Injection - nnmt inhibitor Size:1000 mcg/ml - 10 ml x 3
Pay in 4 interest-free payments of $7.49 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 2 - Oct 7